

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/040260 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 487/04 (2006.01)
C07D 451/02 (2006.01) A61K 31/4184 (2006.01)
C07D 451/04 (2006.01) A61P 1/16 (2006.01)
C07D 403/10 (2006.01) A61P 1/18 (2006.01)
C07D 405/12 (2006.01) A61P 13/12 (2006.01)
C07D 471/04 (2006.01) A61P 11/00 (2006.01)
C07D 487/10 (2006.01)

(21) International Application Number:

PCT/US2021/046421

(22) International Filing Date:

18 August 2021 (18.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/067,587 19 August 2020 (19.08.2020) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **YOON, David, S.**; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Prince-
ton, New Jersey 08543 (US). **REGUEIRO-REN, Ali-**
cia; c/o Bristol-Myers Squibb Company, Route 206 and
Province Line Road, Princeton, New Jersey 08543 (US).
MANDLER, Michael; c/o Bristol-Myers Squibb Compa-
ny, Route 206 and Province Line Road, Princeton, New
Jersey 08543 (US). **POSY, Shoshana, L.**; c/o Bristol-My-
ers Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US).

(74) Agent: **GREENBLATT, Gary, D.** et al.; Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: IH-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS



(57) Abstract: The present invention relates to IH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).



WO 2022/040260 A1